Your browser doesn't support javascript.
loading
Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
Berlin, Eva; Yegya-Raman, Nikhil; Garver, Elizabeth; Li, Taoran; Lin, Lilie L; Taunk, Neil K.
Afiliação
  • Berlin E; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Yegya-Raman N; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Garver E; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Li T; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Lin LL; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Taunk NK; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, USA. Electronic address: taunk@pennmedicine.upenn.edu.
Gynecol Oncol ; 172: 92-97, 2023 05.
Article em En | MEDLINE | ID: mdl-37003073
ABSTRACT

OBJECTIVE:

To characterize long-term toxicity and disease outcomes with whole pelvis (WP) pencil beam scanning proton radiation therapy (PBS PRT) for gynecologic malignancies.

METHODS:

We reviewed 23 patients treated from 2013 to 2019 with WP PBS PRT for endometrial, cervical, and vaginal cancer. We report acute and late Grade (G)2+ toxicities, graded by Common Terminology Criteria for Adverse Events, Version 5. Disease outcomes were assessed by Kaplan-Meier method.

RESULTS:

Median age was 59 years. Median follow up was 4.8 years. 12 (52.2%) had uterine cancer, 10 (43.5%) cervical, 1 (4.3%) vaginal. 20 (86.9%) were treated post-hysterectomy. 22 (95.7%) received chemotherapy, 12 concurrently (52.2%). The median PBS PRT dose was 50.4GyRBE (range, 45-62.5). 8 (34.8% had para-aortic/extended fields. 10 (43.5%) received brachytherapy boost. Median follow up was 4.8 years. 5-year actuarial local control was 95.2%, regional control 90.9%, distant control 74.7%, both disease control and progression-free survival 71.2%. Overall survival was 91.3%. In the acute period, 2 patients (8.7%) had G2 genitourinary (GU) toxicity, 6 (26.1%) had gastrointestinal (GI) G2-3 toxicity, 17 (73.9%) had G2-4 hematologic (H) toxicity. In the late period, 3 (13.0%) had G2 GU toxicity, 1 (4.3%) had G2 GI toxicity, 2 (8.7%) had G2-3H toxicity. The mean small bowel V15Gy was 213.4 cc. Mean large bowel V15 Gy was 131.9 cc.

CONCLUSIONS:

WP PBS PRT for gynecologic malignancies delivers favorable locoregional control. Rates of GU and GI toxicity are low. Acute hematologic toxicity was most common, which may be related to the large proportion of patients receiving chemotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Braquiterapia / Radioterapia de Intensidade Modulada / Terapia com Prótons / Gastroenteropatias / Neoplasias dos Genitais Femininos Tipo de estudo: Etiology_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Braquiterapia / Radioterapia de Intensidade Modulada / Terapia com Prótons / Gastroenteropatias / Neoplasias dos Genitais Femininos Tipo de estudo: Etiology_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article